XPHYTO THERAPEUTICS
Commented by Armin Schulz on November 2nd, 2022 | 14:10 CET
BioNTech, XPhyto Therapeutics, MorphoSys - Biotech stocks facing a renaissance?
While the Corona pandemic plunged many companies into crisis, the biotech sector was the big winner. The fastest vaccine developers raked in record profits and are still profiting from vaccine orders today. Meanwhile, the Corona Crisis is no longer the focus of attention in many parts of the world. This is one of the reasons why the NASDAQ Biotech Index suffered significant losses until the end of September. In some cases, the shares of biotechnology companies were trading below their cash levels. Since October, things have been on the upswing. Reason enough to take a look at three interesting biotech companies.
ReadCommented by Stefan Feulner on October 25th, 2022 | 14:43 CEST
Core One Labs, XPhyto, BioNTech - The second biotech series moves forward
The enormously rapid development of the various COVID vaccines by historical standards showed how important biotechnology already is for humanity. Previously unknown companies such as BioNTech, Valneva and CureVac took center stage on the stock market and were able to multiply their share prices within a few months. Even after the pandemic, the biotech wheel continues to turn. Enormous growth opportunities are said to exist in the market for psychedelic drugs. Here, young growth companies are waiting in the wings with the potential to multiply their share prices in the future.
ReadCommented by André Will-Laudien on October 12th, 2022 | 11:31 CEST
Biotech in the scope: BioNTech, XPhyto Therapeutics, MorphoSys, Valneva - The cards are reshuffled!
Cancer remains one of the greatest afflictions of our time, along with cardiovascular disease. Despite the tremendous progress already made in the fight against cancer, there remains an unmet medical need for many types of cancer. Cancer was responsible for nearly 10 million deaths worldwide in 2020. Other diseases, such as Alzheimer's and Parkinson's, also continue to be the focus of research. How is the biotech industry faring after the pandemic and during the stock market storm?
ReadCommented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST
Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life
About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...
ReadCommented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST
BioNTech, XPhyto, Valneva - It is over!
In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.
ReadCommented by André Will-Laudien on July 28th, 2022 | 14:20 CEST
Finding the next BioNTech: MorphoSys, XPhyto Therapeutics, Formycon - Who will make the breakthrough?
The Mainz-based biotech Company BioNTech has shown the way with Cormirnaty®: stringent research and adherence to milestones ultimately lead to success. The main and founding investors Strüngmann are still on board as long-term investors with over 40% even after the price correction. The mRNA technology is now mutating into the basis for a whole new class of drugs, and BioNTech could thus become a new German pharmaceutical giant. The brothers from Tegernsee know what they are talking about. Their start-up capital came from the first major exit after they sold their generic drug manufacturer Hexal, founded in 1979, to Novartis for EUR 5.65 billion in 2005. Since then, they have continued to invest in biotechnology through their family office. The challenge is to find the next BioNTech.
ReadCommented by Nico Popp on July 21st, 2022 | 11:24 CEST
Time is of the essence! Bavarian Nordic, XPhyto, Valneva
Resourceful investors always bet on corresponding stocks when new pathogens or disease patterns become known. BioNTech was one of the early movers in the case of COVID-19, but so were several other stocks that are now unknown again. Even for monkeypox, there have long been stocks that have profited - for example, the share of smallpox vaccine manufacturer Bavarian Nordic which recently rose sharply. We explain the hype around pharmaceutical stocks and outline where there could still be potential now.
ReadCommented by Fabian Lorenz on July 13th, 2022 | 14:27 CEST
MorphoSys facing a takeover? Exciting autumn ahead for BioNTech and XPhyto
Biotech investors could be in for an exciting autumn. After some sharp price corrections, positive things are happening again in the biotech sector. For one thing, the takeover carousel. It all started in June when Pfizer announced the acquisition of migraine specialist Biohaven for USD 11.6 billion, and GlaxoSmithKline plans to swallow Sierra Oncology for around USD 1.9 billion. Recent deals include the acquisitions of ViaCyte, La Jolla Pharmaceutical and Pliant Therapeutics. MorphoSys is also a possible takeover candidate. It could be a win-win for the German biotech company if the price is attractive. Xphyto could also see at least one investment, as a market-ready product has great potential.
ReadCommented by Stefan Feulner on July 6th, 2022 | 11:58 CEST
Rheinmetall and Hensoldt stumble, good opportunities in XPhyto and Deutsche Telekom
As a result of the shockingly weak economic data from the eurozone, the euro fell to its lowest level in almost 20 years with an exchange rate of 1.028 against the US dollar and is currently not far from parity. This crash was followed by European equities, with the DAX recording a new low for the year. Even last week's high flyers, defense stocks, were hit hard with double-digit daily losses. Despite the current correction, there are attractive long-term, anti-cyclical entry opportunities in many sectors at current levels.
ReadCommented by André Will-Laudien on June 30th, 2022 | 13:49 CEST
Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?
Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?
Read